Evidence map›Paper›PMID 39990442›Full record

ArticlebioRxiv : the preprint server for biology2025

Identification of a multi-omics factor predictive of long COVID in the IMPACC study.

Gisela Gabernet, Jessica Maciuch, Jeremy P Gygi, John F Moore, Annmarie Hoch, Caitlin Syphurs, Tianyi Chu, Naresh Doni Jayavelu, David B Corry, Farrah Kheradmand and 45 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

55 authors.

Gisela GabernetYale School of Medicine, New Haven, CT 06511, USA.
Jessica MaciuchNorthwestern Feinberg School of Medicine, Chicago, IL 60611, USA.
Jeremy P GygiYale School of Medicine, New Haven, CT 06511, USA.
John F MooreThe University of Texas at Austin, Austin, TX 78712, USA.
Annmarie HochClinical and Data Coordinating Center (CDCC), Precision Vaccines Program, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Caitlin SyphursClinical and Data Coordinating Center (CDCC), Precision Vaccines Program, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Tianyi ChuYale School of Medicine, New Haven, CT 06511, USA.
Naresh Doni JayaveluBenaroya Research Institute, University of Washington, Seattle, WA 98101, USA.
David B CorryBaylor College of Medicine and the Center for Translational Research on Inflammatory Diseases, Houston, TX 77030, USA.
Farrah KheradmandBaylor College of Medicine and the Center for Translational Research on Inflammatory Diseases, Houston, TX 77030, USA.
Lindsey R BadenBrigham and Women's Hospital, Harvard Medical School, Boston, MA 02115.
Rafick-Pierre SekalyCase Western Reserve University and University Hospitals of Cleveland, Cleveland, OH 44106, USA.
Grace A McComseyCase Western Reserve University and University Hospitals of Cleveland, Cleveland, OH 44106, USA.
Elias K HaddadDrexel University, Tower Health Hospital, Philadelphia, PA 19104, USA.
Charles B CairnsDrexel University, Tower Health Hospital, Philadelphia, PA 19104, USA.
Nadine RouphaelEmory School of Medicine, Atlanta, GA 30322, USA.
Ana Fernandez-SesmaIcahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Viviana SimonIcahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Jordan P MetcalfOklahoma University Health Sciences Center, Oklahoma City, OK 73104.
Nelson I Agudelo HiguitaOklahoma University Health Sciences Center, Oklahoma City, OK 73104.
Catherine L HoughOregon Health & Science University, Portland, OR 97239, USA.
William B MesserOregon Health & Science University, Portland, OR 97239, USA.
Mark M DavisStanford University School of Medicine, Palo Alto, CA 94305, USA.
Kari C NadeauStanford University School of Medicine, Palo Alto, CA 94305, USA.
Bali PulendranStanford University School of Medicine, Palo Alto, CA 94305, USA.
Monica KraftUniversity of Arizona, Tucson AZ 85721, USA.
Chris BimeUniversity of Arizona, Tucson AZ 85721, USA.
Elaine F ReedDavid Geffen School of Medicine at the University of California Los Angeles, Los Angeles CA 90095, USA.
Joanna SchaenmanDavid Geffen School of Medicine at the University of California Los Angeles, Los Angeles CA 90095, USA.
David J ErleUniversity of California San Francisco, San Francisco, CA 94115, USA.
Carolyn S CalfeeUniversity of California San Francisco, San Francisco, CA 94115, USA.
Mark A AtkinsonUniversity of Florida, Gainesville, FL 32611, USA.
Scott C BrackenridgeUniversity of Florida, Gainesville, FL 32611, USA.
Esther MelamedThe University of Texas at Austin, Austin, TX 78712, USA.
Albert C ShawYale School of Medicine, New Haven, CT 06511, USA.
David A HaflerYale School of Medicine, New Haven, CT 06511, USA.
Al OzonoffClinical and Data Coordinating Center (CDCC), Precision Vaccines Program, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Steven E BosingerEmory School of Medicine, Atlanta, GA 30322, USA.
Walter EckalbarUniversity of California San Francisco, San Francisco, CA 94115, USA.
Holden T MaeckerStanford University School of Medicine, Palo Alto, CA 94305, USA.
Seunghee Kim-SchulzeIcahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Hanno SteenPrecision Vaccines Program, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Florian KrammerIcahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Kerstin WestendorfLa Jolla Institute for Immunology, La Jolla, CA 92037, USA.
IMPACC Network
Bjoern PetersLa Jolla Institute for Immunology, La Jolla, CA 92037, USA.
Slim FouratiNorthwestern Feinberg School of Medicine, Chicago, IL 60611, USA.
Matthew C AltmanBenaroya Research Institute, University of Washington, Seattle, WA 98101, USA.
Ofer LevyPrecision Vaccines Program, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Kinga K SmolenPrecision Vaccines Program, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Ruth R MontgomeryYale School of Medicine, New Haven, CT 06511, USA.
Joann Diray-ArceClinical and Data Coordinating Center (CDCC), Precision Vaccines Program, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Steven H KleinsteinYale School of Medicine, New Haven, CT 06511, USA.
Leying GuanYale School of Medicine, New Haven, CT 06511, USA.
Lauren I R EhrlichThe University of Texas at Austin, Austin, TX 78712, USA.ORCID 0000-0002-1697-1755

Funding

Using a tonsil organoid system to probe conditions for the induction of protective antibody and T cell responses to influenza.U19AI057229 · NIAID · STANFORD UNIVERSITY · PI Mark Morris Davis · 2003 to 2026
$88.5M
Translation of immunologic technologies from basic research into pre-clinical nonU19AI062629 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI COGGESHALL, KENNETH MARK · 2004 to 2023
$56.2M
Systems investigation of vaccine responses in B cell depleted autoimmune patientsU19AI089992 · NIAID · YALE UNIVERSITY · PI Albert C Shaw · 2010 to 2026
$50.4M
Project 3 - Ex vivo immune profiling of dengue viruses and vaccinesU19AI118610 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HARRIS, EVA · 2015 to 2021
$46.6M
Systems Biological Analysis of Innate and Adaptive Responses to VaccinationU19AI090023 · NIAID · EMORY UNIVERSITY · PI AHMED, RAFI, LI, SHUZHAO · 2010 to 2021
$45.0M
Understanding Asthma EndotypesU19AI077439 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PRESCOTT G WOODRUFF · 2008 to 2026
$41.1M
Clinical and Translational Science Collaborative of Northern Ohio, Catalyzing Linkages to Equity in Health (CLE Health)UM1TR004528 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI GRACE A MCCOMSEY · 2023 to 2026
$32.1M
Transcriptomics to define biomarkers of neonatal vaccine immunogenicityU19AI118608 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI LEVY, OFER · 2017 to 2021
$24.7M
HIPC Data Coordinating CenterU01AI167892 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI Steven H. Kleinstein, Bjoern Peters · 2022 to 2026
$18.7M
Tollip inhibits IL-33 signaling during airway influenza virus infectionU19AI125357 · NIAID · UNIVERSITY OF ARIZONA · PI KRAFT, MONICA, VERCELLI, DONATA · 2016 to 2025
$14.7M
Systems biological assessment of T cell responses to vaccinationU19AI167903 · NIAID · STANFORD UNIVERSITY · PI BALI PULENDRAN · 2022 to 2026
$13.2M
Project 3: Mapping the Evolution of Chronic Transplant Injury in the Context of CMV InfectionU19AI128913 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI REED, ELAINE F, SARWAL, MINNIE M · 2017 to 2021
$11.2M
NCATS NIH HHS UM1 TR004528NIAID NIH HHS R01 AI104870NIAID NIH HHS R01 AI122220NIAID NIH HHS R01 AI135803NIAID NIH HHS R01 AI145835NIAID NIH HHS U01 AI167892NIAID NIH HHS U19 AI057229NIAID NIH HHS U19 AI062629NIAID NIH HHS U19 AI077439NIAID NIH HHS U19 AI089992NIAID NIH HHS U19 AI090023NIAID NIH HHS U19 AI118608NIAID NIH HHS U19 AI118610NIAID NIH HHS U19 AI125357NIAID NIH HHS U19 AI128910NIAID NIH HHS U19 AI128913NIAID NIH HHS U19 AI167903NIAID NIH HHS U54 AI142766NIDA NIH HHS T32 DA018926
6 · The paper itself

Abstract

Following SARS-CoV-2 infection, ~10-35% of COVID-19 patients experience long COVID (LC), in which often debilitating symptoms persist for at least three months. Elucidating the biologic underpinnings of LC could identify therapeutic opportunities. We utilized machine learning methods on biologic analytes and patient reported outcome surveys provided over 12 months after hospital discharge from >500 hospitalized COVID-19 patients in the IMPACC cohort to identify a multi-omics "recovery factor". IMPACC participants who experienced LC had lower recovery factor scores compared to participants without LC. Biologic characterization revealed increased levels of plasma proteins associated with inflammation, elevated transcriptional signatures of heme metabolism, and decreased androgenic steroids in LC patients. The recovery factor was also associated with altered circulating immune cell frequencies. Notably, recovery factor scores were predictive of LC occurrence in patients as early as hospital admission, irrespective of acute disease severity. Thus, the recovery factor identifies patients at risk of LC early after SARS-CoV-2 infection and reveals LC biomarkers and potential treatment targets.

Indexed as

androgenic steroidsCOVID-19Heme metabolisminflammationLong COVIDMachine Learningmulti-omicsPASCpatient reported outcomesSARS-CoV-2

Identifiers

PMID39990442
PMCPMC11844572

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.